Gilead Sciences halts Phase II trial of GS 9450 for chronic hepatitis C

NewsGuard 100/100 Score
Apr 20 2010

Gilead Sciences, Inc. (Nasdaq:GILD) today announced the company is stopping its ongoing Phase II clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C. This decision follows reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.

Patient safety is Gilead's top priority, and the company has therefore made the decision to halt this study immediately. Gilead will be conducting a thorough review of all available data to assess future clinical development of the compound.

Source Gilead Sciences

Posted in: Drug Trial News | Disease/Infection News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

New optimized vaccine approach targets Hepatitis C virus variability
Hydrogel with built-in antibiofilm and antioxidative functions promotes faster healing of infected chronic wounds
Link between gut dysbiosis and chronic diseases explored in new study
Are your snacks deadly? New study reveals how ultra-processed foods lead to chronic disease outcomes
Higher dietary niacin intake linked to lower COPD risk, study finds
Chronic underhydration linked to major health risks, study finds
Ultra-processed foods raise chronic kidney disease risk, study shows
Are we eating what's really good for us? New insights into macronutrients and chronic disease

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Vaccines targeting chronic diseases show promise in combatting age-related conditions